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Take-home message: Ulinastatin, a
protease inhibitor, inhibits several pro-
inflammatory proteases and decreases
inflammatory cytokine levels and mortality
in experimental sepsis. In this pilot study,
intravenous administration of ulinastatin
(200,000 IU 12 hourly for 5 days) reduced
mortality, new onset of organ dysfunction,
duration of mechanical ventilation and
hospital stay in patients with severe sepsis
when started within 48 h of onset of failure
of one or more organs.
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Abstract Purpose: Ulinastatin, a
serine protease inhibitor, inhibits
several pro-inflammatory proteases
and decreases inflammatory cytokine
levels and mortality in experimental
sepsis. We studied the effect of uli-
nastatin on 28-day all-cause mortality
in a double-blind trial in patients with
severe sepsis in seven Indian hospi-
tals. Methods: Patients with sepsis
were randomized within 48 h of onset
of one or more organ failures to
receive intravenous administration of
ulinastatin (200,000 IU) or placebo
12 hourly for 5 days. Results: Of
122 randomized subjects, 114 com-
pleted the study (55 receiving
ulinastatin, 59 receiving placebo). At
baseline, the mean APACHE II score
was 13.4 (SD = 4.4), 48 (42 %)
patients were receiving mechanical
ventilation, 58 (51 %) were on
vasopressors, and 35 % had multiple
organ failure. In the modified inten-
tion-to-treat analysis (patients
receiving six or more doses of study
drugs), 28-day all-cause mortality
was 7.3 % with ulinastatin (4 deaths)
versus 20.3 % (12 deaths) with pla-
cebo (p = 0.045). On multivariate
analysis too, treatment with ulinasta-
tin (odds ratio 0.26, 95 % CI
0.07–0.95; p = 0.042) independently
decreased 28-day all-cause mortality.
However, the mortality difference did
not reach statistical significance in the
intention-to-treat analysis [10.2 % (6/
59 deaths) with ulinastatin versus
20.6 % (13/63 deaths) in the placebo
group; p = 0.11]. The ulinastatin
group had lower incidence of new-
onset organ failure (10 vs. 26 patients,
p = 0.003), more ventilator-free days
(mean ± SD 19.4 ± 10.6 days vs.
10.2 ± 12.5 days, p = 0.019), and
shorter hospital stay (11.8 ± 7.1 days
vs. 24.2 ± 7.2 days, p \ 0.001).
Conclusions: In this pilot study,
intravenous administration of uli-
nastatin reduced mortality in patients
with severe sepsis in the modified
intention-to-treat analysis, but not in
the intention-to-treat analysis.
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Introduction
Sepsis is a common cause of morbidity and mortality in
critically ill patients, and its incidence is increasing
worldwide annually [1, 2]. The pathogenesis of sepsis is
complex and is believed to be initiated by the interaction
between pathogen-associated molecular patterns and
pattern recognition receptors on host immune cells [3, 4].
This sets off a series of pro-inflammatory mechanisms
including synthesis and release of cytokines and com-
plement, chemotaxis and activation of neutrophils, and
initiation of coagulation [3–5]. These, in turn, have
widespread effects on other cells including inflammatory
cells, immune response, endocrine and autonomic ner-
vous systems, and vascular endothelium, mainly aimed at
limiting spread or eliminating the infecting pathogen [3–
6]. Current opinion suggests that the systemic inflamma-
tory response syndrome (SIRS) that characterizes severe
sepsis results from an excessive activation of pro-
inflammatory mediators, which have pleiotropic effects
that overwhelm the body’s anti-inflammatory mecha-
nisms, leading to widespread vascular, endothelial, and
organ dysfunction that is often fatal [3–6].
Many of the intermediaries in the systemic inflam-
matory processes are serine proteases. These include
trypsin, thrombin, chymotrypsin, kallikrein, plasmin,
neutrophil elastase, cathepsin, neutrophil protease-3, and
coagulation factors IXa, Xa, XIa, and XlIa [7, 8]. It is now
being recognized that besides their proteolytic activity,
these proteases have an important role in regulation of
inflammation through inter- and intracellular signaling
pathways [8, 9]. To counter-regulate the effect of these
proteases, several protease inhibitors are produced by the
liver in the presence of inflammation; these include acute
phase reactants such as a1-antitrypsin and proteins of the
inter-a-inhibitor family [9]. Urinary trypsin inhibitor is
one such important protease inhibitor found in human
blood and urine; it has been also referred to in the liter-
ature as ulinastatin or bikunin [10, 11]. It is an acidic
glycoprotein (molecular weight 30 kDa) and Kunitz-type
serine protease inhibitor composed of 143 amino acid
residues and includes two Kunitz-type domains [7, 10]. It
is cleaved from the larger inter-a-trypsin inhibitor mole-
cule by neutrophil elastase in the presence of
inflammation, and is believed to play an important anti-
inflammatory role [8–12].
Studies in patients have shown that there is a decrease
in serum levels of ulinastatin in sepsis, with the lowest
levels being found in patients with severe sepsis and
septic shock [12]. As compared to wild-type mice, mor-
tality due to experimental sepsis is higher in genetically
modified knockout mice that lack the genes for synthesis
of urinary trypsin inhibitor [11, 13]. Several preclinical
studies have shown a reduction in the systemic inflam-
matory response and organ dysfunction due to sepsis in
animals treated with ulinastatin [13–17]. On the basis of a
few small clinical studies that have shown a trend towards
reduced mortality and duration of hospitalization with
ulinastatin in severe sepsis [18, 19], some authors have
suggested that ulinastatin may have a role as a novel
therapy in severe sepsis [20, 21]. We therefore conducted
this pilot study to evaluate the efficacy of ulinastatin in
Indian patients with severe sepsis.
Methods
This randomized, double-blind, placebo-controlled trial
was conducted in the intensive care units (ICUs) of seven
tertiary care hospitals in India; the study protocol was
approved by the institutional review boards at each center.
The study protocol is available from the Indian clinical
trials registry at http://www.ctri.nic.in (clinical trial
number CTRI/2009/091/000650).
Adults, aged 18–60 years (both inclusive), with severe
sepsis, admitted to the ICU between September 2009 and
June 2010 were eligible for enrollment into the study.
Sepsis was defined as evidence of infection (defined as
presence of white blood cells in a normally sterile body
fluid, perforated abdominal viscus, evidence of pneumo-
nia, or presence of a condition associated with a high risk
of bacterial infection, e.g., ascending cholangitis), and the
presence of at least three of the four SIRS criteria [22].
Severe sepsis was defined as the presence of sepsis as
defined above, along with dysfunction of at least one
organ or system. Cardiovascular system failure was
defined as systolic blood pressure B90 mmHg or mean
arterial pressure B70 mmHg for at least 1 h despite
adequate fluid resuscitation, or the use of vasopressors to
maintain arterial pressure above these levels or unex-
plained metabolic acidosis (pH B 7.30 or base deficit
C5.0 mmol/L) with plasma lactate greater than 1.5 times
the upper limit of normal. Renal failure was defined as
urine output \0.5 mL/kg/h for 1 h, or serum creatinine
levels greater than 2.5 times the upper limit; respiratory
failure as PaO2/FiO2 B250 in the presence of other dys-
functional organs or B200 if only lung; hematologic
dysfunction by platelet count\80,000/mm3 or 50 % drop
in preceding 3 days [22]. Only patients with organ dys-
function of B48 h duration were eligible for inclusion.
Pregnant or breastfeeding women, patients with
platelet count \30,000/mm3, history of organ transplan-
tation, poorly controlled neoplasm, end-stage chronic
kidney or liver disease, and patients weighing [135 kg
were excluded. Patients in whom limitation of care was
planned or who were expected to die within the next 24 h
were also excluded.
Block randomization (block size of 4) using a com-
puter-generated sequence was used to ensure balance
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between treatments; blinding of the sequence was main-
tained in sealed, opaque envelopes. Blinding of treatment
allocation in participating centers was done using serially
numbered packages of the study medication; package
numbered 1 was to be used for the first patient, and so on.
After obtaining written informed consent, patients were
randomized in a 1:1 ratio to receive ulinastatin or placebo
in addition to standard care. Randomized patients
received an intravenous infusion of either 200,000 IU u-
linastatin (U-tryp, Bharat Serum and Vaccines Ltd, India)
or identical placebo dissolved in 250 mL of 0.9 % saline
given intravenously over 1 h every 12 h for 5 days in a
double-blind evaluation. For patients with fluid restric-
tion, 100 mL of 0.9 % saline could be used. Infusion
could be interrupted for 1 day, if there was greater than
three times increase in liver enzymes over baseline levels.
In addition to the study medications, patients also
received antibiotics, intravenous fluids, enteral or paren-
teral nutrition, transfusion of blood and blood products,
and supportive care for organ dysfunction including
mechanical or non-invasive ventilation, vasopressors
(noradrenaline, adrenaline, dopamine, or vasopressin), or
dialysis as per the standard treatment protocols followed
in each ICU. Investigators were encouraged to follow the
Surviving Sepsis Campaign guidelines. No concomitant
medications were prohibited in the study.
Baseline characteristics including demographics, pre-
existing conditions, organ dysfunction, infection, and
hematologic and other laboratory tests were assessed
within the 24 h prior to infusion of the first dose of study
medication. Blood samples were also obtained on the day
of discharge. Patients were followed up till 28 days after
the start of treatment. The primary end-point for this study
was 28-day all-cause mortality. Secondary end-points
included onset of new organ failure, duration of vaso-
pressor use, ventilator-free days till day 28, and length of
hospital stay. New-onset organ failure was defined as
occurrence of organ failure after randomization. The
definitions used were the same as those used in inclusion
criteria; liver dysfunction was defined as serum bilirubin
C2.0 mg/dL when bilirubin was \2.0 mg/dL at baseline
and central nervous system failure was defined as Glas-
gow coma scale (GCS) B10 after randomization in
patients who had baseline GCS [10.
Statistical analysis
Data analysis was carried out using the Graph Pad Instat
and SPSS version 14 software package. Forward stepwise
multiple logistic regression analysis was used for assess-
ment of the primary end-point. Other categorical
data were compared between the treatment groups by
Pearson’s Chi-squared test or Fisher’s exact test, as
appropriate. The unpaired t test was used for continuous
variables and the Mann–Whitney test for ordinal data like
the APACHE II score.
Sample size calculation was performed assuming a
28-day all-cause mortality of 30 % in the control group
and 10 % in the study group. A sample size of 59 com-
pleted patients in each group was required to attain a
power of 80 % at a significance level of 5 %. The primary
efficacy end-point of 28-day all-cause mortality was
assessed in the modified intention-to-treat population
which was defined a priori. This primary analysis popu-
lation included all randomized patients who had received
at least six doses of the study medication. Safety was
assessed in the safety population, defined as all subjects
who received even a single dose of the study medication.
Mortality difference in the intention-to-treat population
that included all randomized subjects was analyzed as a
secondary end-point.
Results
During the 10-month study period, 224 patients met the
inclusion criteria. Of these, 102 patients were excluded;
99 because of presence of one or more exclusion criteria,
or refusal of consent to participate in the study and three
patients were not enrolled as they were expected to die
within 24 h (Fig. 1). Of the 122 randomized subjects, 114
completed the study (55 subjects in the ulinastatin group
and 59 subjects in the control group). Five subjects dis-
continued from the study (three subjects withdrew
consent and two due to protocol violation). Three patients
who died within 48 h of enrollment were not included for
analysis in the modified intention-to-treat population. Of
the 114 patients who completed the study, one patient in
the ulinastatin group received six doses and one patient
each in the placebo group received six and seven doses;
all others received the 10 scheduled doses of study
medications.
Baseline characteristics
At baseline, the two treatment groups were similar with
respect to demographic characteristics, cause of sepsis,
number of organs affected, pattern of organ dysfunction,
and need for vasopressors or mechanical ventilation
(Table 1). Infection was microbiologically confirmed in
26 patients (23 %). Approximately 35 % of patients had
multiple organ failure at baseline, 51 % required vaso-
pressors, and 42 % received mechanical ventilation. For
details of organisms causing sepsis and antibiotics used,
see Electronic Supplementary Material.
832
Outcomes
The 28-day mortality, the primary end-point of this study,
showed a significant difference (Table 2) in the two
treatment groups; there were four deaths (7.3 %) in the
ulinastatin group versus 12 deaths (20.3 %) in the placebo
group. On stepwise multiple logistic regression, treatment
with ulinastatin was found to produce a statistically sig-
nificant decrease in risk of death (odds ratio 0.26, 95 %
confidence limits 0.07–0.95; p = 0.042). Other variables
independently associated with mortality were acute renal
failure and mechanical ventilation at baseline (Table 3).
Of the four deaths in the ulinastatin group one patient
each died as a result of ARDS, acute renal failure,
refractory shock, and multiple organ failure. Of the 12
deaths in the placebo group five patients died as a result of
ARDS, five as a result of refractory shock, and one each
as a result of intracranial hemorrhage and multiple organ
failure. All deaths were attributed by the investigators to
progression of underlying sepsis. The Kaplan–Meier plot
for survival in the two groups is shown in Fig. 2.
Among the secondary end-points, there were 6 deaths
(10.2 %) in the ulinastatin group (n = 59) in the inten-
tion-to-treat population which included all randomized
subjects versus 13 deaths (20.6 %) in the control group
(n = 63; p = 0.11). New onset of organ dysfunction was
seen in 10 subjects in the ulinastatin group and 26
subjects in the placebo group (p = 0.003). Number of
ventilator-free days up to day 28 (mean ± SD) was sig-
nificantly more (19.4 ± 10.6 days) in the ulinastatin
group and 10.2 ± 12.5 days in the placebo group
(p = 0.019). Mean hospital stay too was less in the uli-
nastatin group by an average of 12.4 days (p = 0.001).
Complications
Intracranial hemorrhage was the only unexpected serious
adverse event in one patient; this patient was from the
placebo group. There were no infusion-related adverse
events associated with treatment with ulinastatin.
Discussion
This prospective, double-blind, randomized, placebo-
controlled trial of ulinastatin in patients with severe sepsis
showed that intravenous administration of ulinastatin in a
dose of 200,000 units twice daily for 5 days was associ-
ated with a reduction in 28-day all-cause mortality (the
primary end-point) to 7.3 versus 20.3 % in the placebo
control group. A few small studies, published in Chinese-
language journals, have shown lower mortality in patients
Fig. 1 CONSORT diagram of
the study
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treated with ulinastatin [19, 23, 24]. Small randomized
controlled trials have also been conducted by a single
group of investigators comparing standard treatment with
intravenous administration of ulinastatin in combination
with alpha thymosin and found a reduction of mortality in
patients with severe sepsis [25–27]. Since these studies
have all used a combination of two novel agents, it is
unclear whether the survival benefit seen was due to
either one of these agents, or the combination. A small
Korean study showed that mortality was lower in patients
Table 1 Baseline
characteristics in patients with
severe sepsis randomized to
placebo and ulinastatin
treatment groups
Characteristics Placebo group (n = 59) Ulinastatin group (n = 55) p value
Age (years)b 36.7 ± 12.5 37.5 ± 12.9 0.70
Gender
Males 50 (85 %) 38 (69 %) 0.05
Females 9 (15 %) 17 (31 %)
Serum creatinine (mg/dL)c 1.0 (0.81, 1.39) 1.0 (0.8, 1.57) 0.97
Platelet count (9103/lL)c 163 (101, 264) 191 (115, 242) 0.44
Total leucocyte count (9103/lL)c 12.8 (8.1, 21.0) 13.6 (7.4, 18.3) 0.55
Serum C reactive protein (mg/L) 132 ± 116 104 ± 112 0.41
Systemic inflammatory response
3 of 4 SIRS criteria 33 (56 %) 27 (49 %) 0.46
4 of 4 SIRS criteria 26 (44 %) 28 (51 %)
Organ dysfunctiona
Cardiovascular 31 (52.5 %) 28 (50.9 %) 0.86
Renal 9 (15.3 %) 8 (14.5 %) 0.92
Respiratory 27 (45.8 %) 29 (52.7 %) 0.46
Hematological 10 (16.9 %) 8 (14.5) 0.73
Metabolic acidosis 8 (13.6 %) 4 (7.3 %) 0.27
Central nervous system 7 (11.9 %) 8 (14.6 %) 0.67
Number of organs affected
One organ 38 (64.4 %) 36 (65.5 %) 0.91
Two organs 17 (28.8 %) 16 (29.1 %)
Three organs 3 (5.1 %) 3 (5.5 %)
Four organs 1 (1.7 %) 0
Infection causing sepsis
Respiratory 25 22 0.79
Abdominal 22 18
Urinary tract 4 4
Central nervous system 0 1
Skin and soft tissue 4 3
Bloodstream infection 4 7
Type of infection
Community-acquired 44 (75 %) 42 (76 %) 0.82
Nosocomial 15 (25 %) 13 (24 %)
Organisms isolated
Gram negative organisms 11 7 0.66
Gram positive organisms 3 2
Candida spp. 1 2
APACHE II scoreb 13.5 ± 6.5 13.2 ± 5.9 0.81
Vasopressors use 30 (50.8 %) 28 (50.9 %) 0.99




Diabetes mellitus 6 9 0.96
COPD 4 5
Chronic liver disease 3 2
Tuberculosis 4 4
Congestive heart failure 4 2
HIV with AIDS 1 1
Chronic kidney disease 1 1
Stroke 0 1
Autoimmune vasculitis 1 1
No comorbid conditions 37 38
a Some patients had more than one organ dysfunction or comorbid condition
b Values are mean ± standard deviation
c Values are median (interquartile range)
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with severe sepsis treated with ulinastatin (18.6 vs. 27 %
in the control group) [18]. Our results further corroborate
these studies and suggest that treatment with ulinastatin
may reduce mortality in severe sepsis in humans.
Highly selective serine protease inhibitors that act on
only a few steps in the multipronged inflammatory
response involved in the pathogenesis of sepsis like
coagulation (tissue factor pathway inhibitor, activated
protein C, thrombomodulin, and antithrombin III), com-
plement cascade (C1 inhibitor), or neutrophil elastase
(sivelestat) have failed to provide substantial clinical
benefit in clinical trials [3–6, 21]. In contrast, ulinastatin
inhibits a wide variety of pro-inflammatory serine prote-
ase enzymes including trypsin, thrombin, kallikrein,
plasmin, cathepsin, neutrophil elastase, neutrophil prote-
ase-3, and coagulation factors IXa, Xa, XIa, and XlIa [7–
11, 28]. Although the exact mechanism of action of uli-
nastatin in sepsis is not clear, it is likely that it may
attenuate the inflammatory response by acting at multiple
sites. In animal models of sepsis, exogenously adminis-
tered ulinastatin has been shown to reduce levels of TNF-
a, IL-1, IL-6, cytokine-induced neutrophil chemoattrac-
tant-1 (CINC-1), myeloperoxidase, free oxygen radicals,
Table 2 Outcomes in patients with severe sepsis in the placebo and ulinastatin groups
Placebo group (n = 59) Ulinastatin group (n = 55) p value
28-day all-cause mortality 12 (20.3 %) 4 (7.3 %) 0.045*
New-onset organ dysfunctiona
Cardiovascular 9 4 0.18
Respiratory 8 4 0.27
Hematological 7 4 0.41
Hepatic 3 2 1.0
Renal 4 2 0.68
Central nervous system 3 2 1.0
Total number of patients with new-onset organ dysfunction 26 10 0.003
Duration of vasopressor use (days) 1.7 ± 2.1 1.7 ± 1.9 0.92
Duration of mechanical ventilator (days) 11.9 ± 9.6 7.5 ± 7.5 0.18
Ventilation-free days (till day 28) 10.2 ± 12.5 19.4 ± 10.6 0.019
Length of hospital stay (days) 24.2 ± 7.2 11.8 ± 7.1 \0.001
* p value is by univariate analysis. Multivariate analysis results are
in Table 3
a New-onset organ dysfunction was defined as organ dysfunction
occurring after administration of the first dose of the study medi-
cation. Criteria used for individual organ dysfunction were same as
those used for inclusion in the study. In addition, liver dysfunction
was defined as post-baseline serum bilirubin C2.0 mg/dL when
bilirubin was \2.0 mg/dL at baseline and central nervous system
dysfunction was defined as post-baseline GCS B10 when baseline
GCS was [10
Table 3 Variables associated with 28-day all-cause mortality on forward stepwise multiple logistic regression analysis
Variable Odds ratioa (OR) 95 % CI of OR p value
Renal failure 6.37 1.70–23.8 0.006
Need for mechanical ventilation 3.36 1.01–11.2 0.048
Treatment with ulinastatin 0.26 0.07–0.95 0.042
Treatment with ulinastatin was independently associated with
decreased mortality compared with treatment with placebo after
adjusting for other baseline characteristics including age, gender,
Glasgow coma scale, specific organ system failure, number of
organs failed, need for vasopressors and need for mechanical
ventilation
a OR\1 indicates reduced risk of death; OR[1 indicates increased
risk of death
Fig. 2 Kaplan–Meier analysis of the probability of survival of
patients with severe sepsis treated with ulinastatin or placebo
(modified intention-to-treat cohort)
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high mobility group box 1 (HMGB1), interleukin (IL)-6,
interleukin-8 (IL-8), malondialdehyde, and soluble inter-
cellular adhesion molecule-1 (sICAM-1) in serum and in
organs like lung, kidney, and intestine of rats with lipo-
polysaccharide-induced SIRS [13–16, 28–34]. Ulinastatin
also decreases phosphorylation of p38 mitogen-activated
protein kinase (p38-MAPK) which in turn attenuates
activation of NF-jB and downregulates expression of the
TNF-a gene [33]. Studies in humans too have shown that
patients with sepsis treated with intravenous administra-
tion of ulinastatin have lower serum levels of pro-
inflammatory markers like TNF-a, IL-1b, IL-4, IL-6, and
C-reactive protein, while levels of anti-inflammatory
cytokine IL-10 was significantly higher [19, 23, 35–37]. It
also reduces thrombomodulin levels and decreases
endothelial dysfunction [38].
Besides reduction in 28-day all-cause mortality, uli-
nastatin also showed beneficial effects on some secondary
end-points in the present study like new-onset organ
dysfunction. Although the duration of vasopressor use
was similar in the two groups, ventilator-free days were
significantly higher in the ulinastatin group (19.4 vs.
10.2 days), suggesting faster recovery from severe sepsis.
This also translated into a shorter mean hospital stay in
the ulinastatin group.
No infusion-related adverse effects were seen in the
present study. Adverse effects with ulinastatin are rare
and were reported in 0.84 % of patients in a Japanese
study [39]. These included increased transaminases
(0.36 %), eosinophilia or leucopenia (0.16 %), rash
(0.13 %), gastrointestinal symptoms (0.08 %), fever
(0.02 %), and local irritation at the injection site
(0.02 %). These were reported in less ill patients with
pancreatitis or when the drug was used prophylactically in
patients undergoing endoscopic retrograde pancreatogra-
phy, for which the drug is licensed in Japan. None of
these effects were seen in the present study, probably
because patients were too sick to complain of these
symptoms.
Our study has some limitations. Firstly, although lar-
ger than previous randomized controlled studies with
ulinastatin, the number of patients is relatively small,
thereby limiting the power of this study. However, power
of a study is more relevant for interpreting results of
clinical trials that show no difference between the two
treatment arms. Secondly, patients aged [60 years were
excluded. This is because unlike in western countries, the
number of elderly patients seeking care in Indian ICUs is
comparatively small, and limitation of care is often opted
for by the family in such cases after a few days of ICU
stay owing to socio-economic and cultural reasons [40,
41]. Thirdly, the baseline APACHE II scores were low
although patients had significant organ dysfunction, as has
also been reported in previous studies from India [42, 43].
This is because the APACHE II score allocates more
points to old age than for maximum possible physiolog-
ical derangement (5 points for age 65–74 years and 6 for
age [75 years) [44]. Moreover, septic encephalopathy is
also more common in the elderly [45], and the highest
possible points for any single physiological variable in the
APACHE II system are assigned to the level of con-
sciousness (APACHE II points = 15 minus Glasgow
coma score) [44]. These two factors alone could add up to
18 points per patient (6 for age and 12 for coma),
accounting for high APACHE II scores in studies from
western countries. These differences may limit the gen-
eralizability of our results to some extent. However, our
study had some strengths too. Whereas all previous
studies with ulinastatin in sepsis have been single-center
studies, this was a multicenter study. Use of a double-
blind design was another strength.
In conclusion, this prospective, multicenter, random-
ized, double-blind, placebo-controlled pilot study in
patients with severe sepsis investigated a novel therapy
directed against the systemic inflammatory response. We
found that 5-day treatment with intravenous administra-
tion of ulinastatin in patients with severe sepsis, when
started within 48 h of organ dysfunction, resulted in a
reduction in 28-day all-cause mortality to 7.3 % from
20.3 % observed in the placebo group. The reduction in
mortality to 10.2 % from 20.6 % in the intention-to-treat
population, however, was short of statistical significance
(p = 0.11). We also found a reduction in new onset of
organ dysfunction, days of mechanical ventilation, and
hospital stay. A larger randomized controlled study with
ulinastatin is needed to further confirm the survival ben-
efit seen in this pilot study and also to investigate its
mechanism of action in humans.
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